As per the deal, Z-Cube will sponsor a research program to be conducted by Prof. Touitou and her group. Z-Cube will have worldwide exclusive rights to develop and commercialize the technology for pain applications while Yissum will receive license fees, milestones and royalty payments. In addition, Z-Cube will have the right to grant sublicenses.
israel-based Yissum Research Development Company has registered 6100 patents covering 1750 inventions; has licensed out 480 technologies and has spun out 65 companies.
Z-Cube – Zambon Company S.p.A. is engaged innthe business of Drug Delivery System (DDS) exploitation. Z-Cube invests in and validates early stage innovative DDS with the potential to generate new products in selected therapeutic areas, with the opportunity to generate NewCos.